Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
Nadda underlined that India’s policy framework is aligned with this transformation
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
Subscribe To Our Newsletter & Stay Updated
